Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial

Abstract Objectives The primary objective of this study is to test the hypothesis that administration of dexamethasone 20 mg is superior to a 6 mg dose in adult patients with moderate or severe ARDS due to confirmed COVID-19. The secondary objective is to investigate the efficacy and safety of dexam...

Повний опис

Бібліографічні деталі

Автори:	Jan Maláska, Jan Stašek, František Duška, Martin Balík, Jan Máca, Jan Hruda, Tomáš Vymazal, Olga Klementová, Jan Zatloukal, Tomáš Gabrhelík, Pavel Novotný, Regina Demlová, Jana Kubátová, Jana Vinklerová, Adam Svobodník, Milan Kratochvíl, Jozef Klučka, Roman Gál, Mervyn Singer, on behalf of the REMED Study Group
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2021-03-01
Серія:	Trials
Предмети:	COVID-19 Randomised controlled trial Protocol ARDS Dexamethasone Ventilator-free days
Онлайн доступ:	https://doi.org/10.1186/s13063-021-05116-9
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!